TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News

Earnings Scheduled For January 30, 2025

Mentions: DB CSWI FISI MO ...

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option.

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024

Takeda Pharmaceutical just reported results for the first quarter of 2024.

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Mentions: HCM LSE -

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Mentions: HCM LSE -

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —

Mentions: HCM LSE -

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking

/PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO: Toshio Fujimoto, "Ciconia") today announced its establishment as a joint...

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Mentions: HCM LSE -

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline